ISRCTN36658311CompletedNot Applicable
A multicentre study of the safety and efficacy of N-acetylcysteine in the treatment of acute liver failure in paediatric patients not caused by acetaminophe
King's College Hospital NHS Foundation Trust (UK)0 sites28 target enrollmentStarted: May 12, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 28
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Enrolment in PALF registry:
- •1. Evidence of acute liver injury
- •2. International normalised ratio (INR) greater than or equal to 1.5 or prothrombin time (PT) greater than or equal to 15 with encephalopathy, or INR greater than or equal to 2.0 or PT greater than or equal to 20 with or without encephalopathy
- •3. Aged less than 18 years, either sex
- •4. Informed consent, obtained from the patient or parent
Exclusion Criteria
- •1. Acute paracetomol toxicity
- •2. Patient on N-acetylcysteine or received N-acetylcysteine during the course of this illness
- •3. Pregnancy
- •4. Known malignancy
- •5. Patient is on a liver support device
- •7. Signs of cerebral herniation
- •8. Intractable hypotension
Investigators
Similar Trials
Completed
Not Applicable
A multi-center study of the safety and efficacy of the percutaneous transvenous mitral annuloplasty system to reduce mitral valve regurgitation in patients with heart failure.mitral regurgitationmitral valve leakage10046973NL-OMON33252Viacor Inc.14
Completed
Not Applicable
A Multicenter study of the safety and efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in patients with hypophosphatasia (HPP)hypophosphatasiaJPRN-UMIN000014816HPP study group20
Active, not recruiting
Not Applicable
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)EUCTR2006-006522-25-BECSL Behring AG28
Active, not recruiting
Not Applicable
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 yearsMedDRA version: 8.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencyEUCTR2006-006522-25-DECSL Behring AG28
Active, not recruiting
Phase 1
A multicenter study on the efficacy and safety of Vivaglobin® in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID)Patients with PID diseases as Common Variable Immunodeficiency (CVID) or X-linked agammaglobulinemia ( XLA), age 1 to 70 yearsMedDRA version: 8.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencyEUCTR2006-006522-25-GRCSL Behring AG18